Evolus, Inc.
EOLS
$-0.44
Change (1 day)
$17.82
Year High
$9.29
Year Low
Categories
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
P/E ratio for Evolus, Inc. (EOLS)
P/E ratio as of 2023: -9.72
According to Evolus, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.72. At the end of 2022 the company had a P/E ratio of -5.66.
P/E ratio history for Evolus, Inc. from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -9.72 |
| 2022 | -5.66 |
| 2021 | -6.92 |
| 2020 | -0.70 |
| 2019 | -3.82 |
| 2018 | -6.20 |
| 2017 | -60.56 |
| 2016 | -10.66 |
| 2015 | -6.87 |